2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Monday, November 11, 2019

9:00AM-11:00AM: Abstract Number: 1448

Ultrasonography of Major Salivary Glands in Primary Sjögren’s Syndrome: Identification of Distinct Evolving Patterns in the Long-Term Follow-up

Sjögrenʼs Syndrome – Basic & Clinical Science Poster II

9:00AM-11:00AM: Abstract Number: 1360

Ultrasound Guided Synovial Biopsies Safely Aid in the Assessment of Inflammatory Arthritis

RA – Diagnosis, Manifestations, & Outcomes Poster II: Treatments, Outcomes, & Measures

9:00AM-11:00AM: Abstract Number: 1144

Understanding Clinical Trials Participation Among Individuals of African Descent with Lupus Through the Lens of Critical Race Theory: A Qualitative Analysis

Healthcare Disparities In Rheumatology Poster

9:00AM-11:00AM: Abstract Number: 1332

United States Rheumatology Practice-Based Real-World Evidence of Infusion Reactions in Rheumatoid Arthritis Patients Treated with Intravenous Golimumab or Infliximab: Impact of Prior Biologic Exposure and Methotrexate Utilization

RA – Diagnosis, Manifestations, & Outcomes Poster II: Treatments, Outcomes, & Measures

9:00AM-11:00AM: Abstract Number: 1219

Uric Acid Level as a Predictor of Long Term Mortality in Advanced Age Population

Metabolic & Crystal Arthropathies Poster II: Clinical Trials & Basic Science

9:00AM-11:00AM: Abstract Number: 1037

Urinary C3d Is a Good Marker for Monitoring Treatment Response After 3 Months of Induction Treatment in Patients with Biopsy Proven Lupus Nephritis

SLE – Etiology & Pathogenesis Poster I

9:00AM-11:00AM: Abstract Number: 1118

US Community Rheumatologists’ Knowledge and Perceptions of Biosimilar Expanded Indication Approval by Extrapolation

Health Services Research Poster II – ACR/ARP

9:00AM-11:00AM: Abstract Number: 1672

Use of Rituximab for the Treatment of ANCA-Associated Vasculitis in Canada, 2010-2018

Vasculitis – ANCA-Associated Poster II

9:00AM-11:00AM: Abstract Number: 1246

Using PROMIS Data to Assess Activity of Inflammatory Eye Disease

Miscellaneous Rheumatic & Inflammatory Disease Poster II: Autoinflammation Related Diseases & Therapies

9:00AM-11:00AM: Abstract Number: 1539

Ustekinumab and TNF Inhibitors Similarly Improve Patient-perceived Impact of Psoriatic Arthritis but Differentially Affect the Scale Subdomains: Results from a European Observational Cohort Study

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster II: Treatment of Axial Spondyloarthritis & Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 1165

Utility of Coronary Calcium Scoring (CCS) in the Spectrum of Connective Tissue Disorders (CTDs) for the Evaluation of Subclinical Coronary Atherosclerosis – a Systematic Review

Imaging Of Rheumatic Diseases Poster II

9:00AM-11:00AM: Abstract Number: 1361

Utility of Rheumatoid Arthritis Impact of Disease (RAID) in Routine Care; Identification of Patients Achieving DAS28 Remission or Low Disease Activity, and Burden of Unmet Patient Reported Outcomes

RA – Diagnosis, Manifestations, & Outcomes Poster II: Treatments, Outcomes, & Measures

9:00AM-11:00AM: Abstract Number: 1210

Utilization of a Multispecialty Team for the Diagnosis of Giant Cell Arteritis Reduces Patient Morbidity

Measures Of Healthcare Quality Poster II: Improving Care

9:00AM-11:00AM: Abstract Number: 1731

Validation of the 2017 Weighted Criteria in Pediatric Systemic Lupus Erythematosus (SLE)

Pediatric Rheumatology – ePoster II: SLE, Juvenile Dermatomyositis, & Scleroderma

9:00AM-11:00AM: Abstract Number: 1571

Validity Evidence Supports the Use of Automated Neuropsychological Assessment Metrics (ANAM) as a Screening Tool for Cognitive Impairment in Patients with Systemic Lupus Erythematosus

SLE – Clinical Poster II: Comorbidities

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].